MediciNova Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de MediciNova disminuyan en un 6.1% al año. Se prevé que el BPA disminuya en un 4.8% al año.
Información clave
-6.1%
Tasa de crecimiento de los beneficios
-4.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 28.5% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 25 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Aug 28We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15The MediciNova Riddle: Worth Unravelling
Apr 26MediciNova inks $20M securities purchase agreement with 3D Investment Partners
Jan 12MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
Dec 29MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Dec 29Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | N/A | -12 | N/A | N/A | 1 |
12/31/2025 | N/A | -12 | N/A | N/A | 1 |
12/31/2024 | N/A | -11 | N/A | N/A | 1 |
9/30/2024 | N/A | -10 | -9 | -9 | N/A |
6/30/2024 | 1 | -8 | -9 | -9 | N/A |
3/31/2024 | 1 | -8 | -8 | -8 | N/A |
12/31/2023 | 1 | -9 | -7 | -7 | N/A |
9/30/2023 | 1 | -10 | -11 | -11 | N/A |
6/30/2023 | N/A | -12 | -12 | -12 | N/A |
3/31/2023 | N/A | -14 | -12 | -12 | N/A |
12/31/2022 | N/A | -14 | -13 | -13 | N/A |
9/30/2022 | N/A | -13 | -13 | -13 | N/A |
6/30/2022 | 0 | -13 | -13 | -13 | N/A |
3/31/2022 | 0 | -13 | -9 | -9 | N/A |
12/31/2021 | 4 | -10 | -9 | -9 | N/A |
9/30/2021 | 4 | -11 | -8 | -8 | N/A |
6/30/2021 | 4 | -11 | -9 | -9 | N/A |
3/31/2021 | 4 | -11 | -12 | -12 | N/A |
12/31/2020 | N/A | -14 | -11 | -11 | N/A |
9/30/2020 | N/A | -13 | -11 | -11 | N/A |
6/30/2020 | N/A | -12 | -9 | -9 | N/A |
3/31/2020 | N/A | -11 | -9 | -9 | N/A |
12/31/2019 | N/A | -13 | -9 | -9 | N/A |
9/30/2019 | N/A | -11 | -8 | -8 | N/A |
6/30/2019 | N/A | -16 | -8 | -8 | N/A |
3/31/2019 | N/A | -15 | -8 | -8 | N/A |
12/31/2018 | N/A | -15 | -9 | -9 | N/A |
9/30/2018 | N/A | -16 | -9 | -9 | N/A |
6/30/2018 | N/A | -13 | N/A | -9 | N/A |
3/31/2018 | N/A | -13 | N/A | -8 | N/A |
12/31/2017 | N/A | -11 | N/A | -7 | N/A |
9/30/2017 | N/A | -11 | N/A | -7 | N/A |
6/30/2017 | N/A | -10 | N/A | -7 | N/A |
3/31/2017 | N/A | -11 | N/A | -7 | N/A |
12/31/2016 | N/A | -11 | N/A | -7 | N/A |
9/30/2016 | N/A | -12 | N/A | -7 | N/A |
6/30/2016 | N/A | -11 | N/A | -7 | N/A |
3/31/2016 | N/A | -10 | N/A | -6 | N/A |
12/31/2015 | N/A | -9 | N/A | -7 | N/A |
9/30/2015 | N/A | -8 | N/A | -7 | N/A |
6/30/2015 | N/A | -9 | N/A | -7 | N/A |
3/31/2015 | N/A | -9 | N/A | -7 | N/A |
12/31/2014 | N/A | -9 | N/A | 1 | N/A |
9/30/2014 | 6 | -3 | N/A | -2 | N/A |
6/30/2014 | 6 | -3 | N/A | -2 | N/A |
3/31/2014 | 6 | -4 | N/A | -3 | N/A |
12/31/2013 | 6 | -4 | N/A | -11 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que MNOV siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que MNOV siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que MNOV siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de MNOV crezcan más rápidamente que el mercado de US.
Ingresos de alto crecimiento: Se prevé que MNOV no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MNOV se prevé que sea elevada dentro de 3 años.